Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elacytarabine plus idarubicin as second induction in AML
2008-008518-38Phase 2Terminated
- Sponsor
- Clavis Pharma
- Start
- Jul 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elacytarabine and idarubicin in acute myeloid leukemia (AML), sponsored by Clavis Pharma. Primary endpoint: Incidence of CR + CRi. Started Jul 2009; status: terminated.
02
Drugs
elacytarabineidarubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2008-008518-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008518-38.